Table 2.

The subgroup analysis between PLR and the prognosis of patients with melanoma.

Variables	No. of studies	No. of patients	Effects model	HR (95% CI)	p	Heterogeneity I2(%) P		Meta-regression p
OS
Total	8	2341	Random	1.67 (1.18–2.38)	0.004	97.2	<0.001
Sample size								0.066
<150	4	321	Fixed	2.56 (1.80–3.64)	<0.001	0	0.595
≥150	4	2020	Random	1.35 (0.88–2.06)	0.166	98.7	<0.001
Disease status								0.105
Non-metastatic	3	1694	Random	1.79 (1.15–2.81)	0.011	67.9	0.044
Metastatic	3	467	Random	1.22 (0.82–1.80)	0.325	71.9	0.028
Mixed	2	180	Fixed	2.46 (1.66–3.67)	<0.001	0	0.768
PLR cutoff value								0.516
<120	4	607	Random	1.83 (1.22–2.74)	0.003	54.8	0.084
≥120	4	1734	Random	1.51 (0.91–2.48)	0.108	88.0	<0.001
PFS
Total	5	1892	Random	1.53 (0.96–2.44)	0.075	95.5	<0.001
Sample size								0.555
<150	2	95	Fixed	1.92 (1.01–3.63)	0.045	0	0.979
≥150	3	1797	Random	1.41 (0.82–2.45)	0.216	97.7	<0.001
Disease status								0.274
Non-metastatic	1	1351	-	1.90 (1.67–2.16)	<0.001	-	-
Metastatic	3	501	Random	1.27 (0.82–1.96)	0.288	54.2	0.112
Mixed	1	40	-	1.95 (0.48–8.02)	0.353	-	-
PLR cut-off value								0.266
<120	2	1391	Fixed	1.90 (1.67–2.16)	<0.001	0	0.970
≥120	3	501	Random	1.27 (0.82–1.96)	0.288	54.2	0.112

OS, overall survival; PFS, progression-free survival; PLR, plate-to-lymphocyte ratio.